Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

Gerd R Burmester(Charité - Universitätsmedizin Berlin), Ricardo Blanco(Marqués de Valdecilla University Hospital), Christina Charles‐Schoeman(University of California, Los Angeles), J. Wollenhaupt(Schön Klinik Hamburg Eilbek), Cristiano A. F. Zerbini(Hospital Heliópolis), Birgitta Benda(Pfizer (United States)), David Gruben(Pfizer (United States)), Gene V. Wallenstein(Pfizer (United States)), Sriram Krishnaswami(Pfizer (United States)), Samuel H. Zwillich(Pfizer (United States)), Tamás Koncz(Pfizer (United States)), Koshika Soma(Pfizer (United States)), John Bradley(Pfizer (United States)), Charles A. Mebus(Pfizer (United States))
The Lancet
January 5, 2013
Cited by 718

Abstract


Related Papers

No related papers found

Powered by citation graph analysis